Prediction of radiation pneumonitis using the effective α/β of lungs and heart in NSCLC patients treated with proton beam therapy

Locoregionally advanced stage non-small cell lung cancer (NSCLC) patients are commonly treated with concurrent radiochemotherapy (RCHT) and adjuvant immunotherapy [1,2]. Treatment intensification strategies in this patient group, e.g., dose escalation to the gross tumor volume (GTV) using stereotactic ablative radiotherapy (SABR) or positron-emission tomography (PET) guided dose-painting strategies, have thus far been unsuccessful, in part due to life-threatening toxicities, such as bleeding from major intrathoracic vessels or radiation pneumonitis (RP) [3,4].

Source: Radiotherapy and Oncology - November 14, 2023 Category: Radiology Authors: Albrecht Wei ß, Steffen Löck, Ting Xu, Zhongxing Liao, Aswin L. Hoffmann, Esther G.C. Troost Tags: Original Article Source Type: research